Patient-provider interactions about cannabis for therapeutic purposes vary as a function of provider type: A pilot study.
Journal
The American journal on addictions
ISSN: 1521-0391
Titre abrégé: Am J Addict
Pays: England
ID NLM: 9208821
Informations de publication
Date de publication:
24 Oct 2024
24 Oct 2024
Historique:
revised:
30
09
2024
received:
30
05
2024
accepted:
04
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
24
10
2024
Statut:
aheadofprint
Résumé
Limited evidence guides the efficacy and safety of cannabis for therapeutic purposes (CTP). Healthcare providers lack requisite knowledge to advise and support patients. This study aimed to describe and compare several aspects of initial CTP interactions across different provider types. Adult cannabis consumers (N = 507) from the United States completed an anonymous online survey about their initial CTP interaction with their healthcare provider. Providers were categorized into four groups (Mental Health [MH], Family Medicine [FM], Medical Clinics [MC], and Other Specialty [OS]). Analyses compared several aspects of the interaction (e.g., risk mitigation, recommendations, satisfaction/confidence) across groups. Less than half of the sample reported discussion of cannabis risks (44.0%) or follow-ups at subsequent visits (46.7%). Recommendations (where to obtain, consumption method, dose, frequency, and authorization) were uncommon (9.7%-25.2%). While the MH group reported the highest rates of risk mitigation behaviors, regression models adjusted for sociodemographic and cannabis characteristics were largely nonsignificant. For recommendations, the MC group was more likely than the MH group to report receiving all recommendations (p < .05). Younger age and greater cannabis-related problems increased likelihood of risk mitigation and recommendations. CTP interactions focused on risk but generally lacked comprehensive recommendations that could potentially promote safe use. Data from provider perspectives could support the need for CTP guidelines and develop training for healthcare providers to promote safe CTP practices. For the first time, this study explored several aspects of CTP interactions and compared experiences across a variety of providers.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Limited evidence guides the efficacy and safety of cannabis for therapeutic purposes (CTP). Healthcare providers lack requisite knowledge to advise and support patients. This study aimed to describe and compare several aspects of initial CTP interactions across different provider types.
METHODS
METHODS
Adult cannabis consumers (N = 507) from the United States completed an anonymous online survey about their initial CTP interaction with their healthcare provider. Providers were categorized into four groups (Mental Health [MH], Family Medicine [FM], Medical Clinics [MC], and Other Specialty [OS]). Analyses compared several aspects of the interaction (e.g., risk mitigation, recommendations, satisfaction/confidence) across groups.
RESULTS
RESULTS
Less than half of the sample reported discussion of cannabis risks (44.0%) or follow-ups at subsequent visits (46.7%). Recommendations (where to obtain, consumption method, dose, frequency, and authorization) were uncommon (9.7%-25.2%). While the MH group reported the highest rates of risk mitigation behaviors, regression models adjusted for sociodemographic and cannabis characteristics were largely nonsignificant. For recommendations, the MC group was more likely than the MH group to report receiving all recommendations (p < .05). Younger age and greater cannabis-related problems increased likelihood of risk mitigation and recommendations.
DISCUSSION AND CONCLUSIONS
CONCLUSIONS
CTP interactions focused on risk but generally lacked comprehensive recommendations that could potentially promote safe use. Data from provider perspectives could support the need for CTP guidelines and develop training for healthcare providers to promote safe CTP practices.
SCIENTIFIC SIGNIFICANCE
CONCLUSIONS
For the first time, this study explored several aspects of CTP interactions and compared experiences across a variety of providers.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDA NIH HHS
ID : P30DA029926
Pays : United States
Organisme : NIDA NIH HHS
ID : R01DA050032
Pays : United States
Organisme : NIDA NIH HHS
ID : T32DA037202
Pays : United States
Informations de copyright
© 2024 The American Academy of Addiction Psychiatry (AAAP).
Références
Center for Behavioral Health Statistics and Quality. 2022 National Survey on Drug Use and Health: Detailed tables. Published online 2023. Accessed May 10, 2024. https://www.samhsa.gov/data/report/2022-nsduh-detailed-tables
National Conference of State Legislatures. State Medical Cannabis Laws. Published online June 22, 2023. Accessed May 10, 2024. https://www.ncsl.org/health/state-medical-cannabis-laws
Leung J, Chan G, Stjepanović D, Chung JYC, Hall W, Hammond D. Prevalence and self‐reported reasons of cannabis use for medical purposes in USA and Canada. Psychopharmacology. 2022;239(5):1509‐1519. doi:10.1007/s00213-021-06047-8
Kosiba JD, Maisto SA, Ditre JW. Patient‐reported use of medical cannabis for pain, anxiety, and depression symptoms: systematic review and meta‐analysis. Soc Sci Med. 2019;233:181‐192. doi:10.1016/j.socscimed.2019.06.005
Walsh Z, Gonzalez R, Crosby K, S. Thiessen M, Carroll C, Bonn‐Miller MO. Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev. 2017;51:15‐29. doi:10.1016/j.cpr.2016.10.002
Scherma M, Muntoni AL, Riedel G, Fratta W, Fadda P. Cannabinoids and their therapeutic applications in mental disorders. Dialogues Clin Neurosci. 2020;22(3):271‐279. doi:10.31887/DCNS.2020.22.3/PFADDA
Dierker L, Selya A, Lanza S, Li R, Rose J. Depression and marijuana use disorder symptoms among current marijuana users. Addict Behav. 2018;76:161‐168. doi:10.1016/j.addbeh.2017.08.013
Lev‐Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J. The association between cannabis use and depression: a systematic review and meta‐analysis of longitudinal studies. Psychol Med. 2014;44(4):797‐810. doi:10.1017/S0033291713001438
Ryan JE, McCabe SE, Boyd CJ. Medicinal cannabis: policy, patients, and providers. Policy Polit Nurs Pract. 2021;22(2):126‐133. doi:10.1177/1527154421989609
Zolotov Y, Metri S, Calabria E, Kogan M. Medical cannabis education among healthcare trainees: a scoping review. Complement Ther Med. 2021;58:102675102675. doi:10.1016/j.ctim.2021.102675
Philpot LM, Ebbert JO, Hurt RT. A survey of the attitudes, beliefs and knowledge about medical cannabis among primary care providers. BMC Fam Pract. 2019;20(1):17. doi:10.1186/s12875-019-0906-y
Kruger DJ, Mokbel MA, Clauw DJ, Boehnke KF. Assessing health care providers' knowledge of medical cannabis. Cannabis Cannabinoid Res. 2022;7(4):501‐507. doi:10.1089/can.2021.0032
Szaflarski M, McGoldrick P, Currens L, et al. Attitudes and knowledge about cannabis and cannabis‐based therapies among US neurologists, nurses, and pharmacists. Epilepsy Behav. 2020;109:107102. doi:10.1016/j.yebeh.2020.107102
Kurtzman ET, Greene J. Are patients who trust their providers more likely to use medical cannabis? Am J Hosp Palliat Care. 2023;40(3):264‐270. doi:10.1177/10499091221097090
Kruger DJ, Gerlach J, Kruger JS, Mokbel MA, Clauw DJ, Boehnke KF. Physicians' attitudes and practices regarding cannabis and recommending medical cannabis use. Cannabis Cannabinoid Res. 2024;9(4):e1048‐e1055. doi:10.1089/can.2022.0324
Shrestha S, Dahlke S, Butler JI, et al. How older Canadians access medical cannabis and information about it: a descriptive survey. Cogent Gerontology. 2024;3(1). doi:10.1080/28324897.2024.2303502
Simons J, Correia CJ, Carey KB, Borsari BE. Validating a five‐factor marijuana motives measure: relations with use, problems, and alcohol motives. J Couns Psychol. 1998;45(3):265‐273. doi:10.1037/0022-0167.45.3.265
Adamson SJ, Kay‐Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: the cannabis use disorders identification test‐revised (CUDIT‐R). Drug Alcohol Depend. 2010;110(1‐2):137‐143. doi:10.1016/j.drugalcdep.2010.02.017
Ziemianski D, Capler R, Tekanoff R, Lacasse A, Luconi F, Ware MA. Cannabis in medicine: a national educational needs assessment among Canadian physicians. BMC Med Educ. 2015;15(1):52. doi:10.1186/s12909-015-0335-0
St. Pierre M, Matthews L, Walsh Z. Cannabis education needs assessment among Canadian physicians‐in‐training. Complement Ther Med. 2020;49:102328. doi:10.1016/j.ctim.2020.102328
Hasin DS, Shmulewitz D, Sarvet AL. Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings. Am J Drug Alcohol Abuse. 2019;45(6):623‐643. doi:10.1080/00952990.2019.1569668
Haug NA, Padula CB, Sottile JE, Vandrey R, Heinz AJ, Bonn‐Miller MO. Cannabis use patterns and motives: a comparison of younger, middle‐aged, and older medical cannabis dispensary patients. Addict Behav. 2017;72:14‐20. doi:10.1016/j.addbeh.2017.03.006
Livne O, Budney A, Borodovsky J, et al. Age differences in patterns of cannabis use among an online US sample of adults who consume cannabis frequently. Am J Drug Alcohol Abuse. 2024;50(2):242‐251. doi:10.1080/00952990.2024.2309340
Bonar EE, Goldstick JE, Collins RL, et al. Daily associations between cannabis motives and consumption in emerging adults. Drug Alcohol Depend. 2017;178:136‐142. doi:10.1016/j.drugalcdep.2017.05.006
Hyman SM, Sinha R. Stress‐related factors in cannabis use and misuse: implications for prevention and treatment. J Subst Abuse Treat. 2009;36(4):400‐413. doi:10.1016/j.jsat.2008.08.005
Kroon E, Kuhns L, Hoch E, Cousijn J. Heavy cannabis use, dependence and the brain: a clinical perspective. Addiction. 2020;115(3):559‐572. doi:10.1111/add.14776